Junwei Shi, Ph.D.

Junwei Shi, Ph.D.

Assistant Professor
Assistant Investigator, Abramson Family Cancer Research Institute

Faculty Website

Contact Information
421 Curie Blvd
Philadelphia , 19104-6160
Office: 215-746-5733
Fax: 215-573-6725


Research Interest

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and causes up to 800,000 deaths annually worldwide. My lab focuses on understanding molecular pathways that support HCC growth. A major clinical challenge for HCC is that most patients are diagnosed at advanced stages, and no curative treatments are currently available. The multikinase inhibitor Sorafenib is the only approved therapy for late stage HCC, which confers only an approximately 3-month median survival benefit.

Current areas of interest within the lab include: (1) Defining the functional importance of epigenetic regulators in HCC, (2) Dissecting the signal transduction pathways that are required for HCC maintenance, and (3) Developing new functional genomic tools.

Publication Links